医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The U.S.-India Business Council Expresses Unease Over Supreme Court of India’s Ruling on Novartis Glivec Case: Seeks Reassurance for Investors

2013年04月03日 AM02:40
このエントリーをはてなブックマークに追加


 

NEW DELHI

A decision was issued today by the Supreme Court of India, which denied a patent on Glivec, an innovative cancer medication produced by pharmaceutical company Novartis. The court’s decision cites Section 3 (d) of India’s patent law and states that a patentee must prove enhanced efficacy of a medicine in order to obtain a patent in India.

Over 40 countries including China, Russia, and Taiwan have already granted a patent for Novartis’ Glivec and India now stands out as unique for not granting a patent to this incremental innovation. The denial of the Glivec patent may now exclude from patentability many other significant inventions in the pharmaceuticals area.

U.S.-India Business Council (USIBC) President Ron Somers stated, “Innovation requires the reward and protection of intellectual property. We are certain India’s leadership understands this, and that creating and maintaining an environment that inspires and enables innovation is in India’s ultimate, long-term interest. Such an environment is crucial if India is to attract investment in this or other highly complex sectors.”

“As India declares this the ‘decade of innovation,’ we hope that the government of India will implement policies and practices that promote innovation, fostering an environment that encourages India’s smartest minds to produce new cures and treatments, as well as original technologies in other sectors,” said Somers. “We believe that incremental innovation is an area where India has a lot to offer and, in particular, where its robust generics business can start to take positive steps towards innovation by improving on therapies that already exist. We recognize the importance of generics to the contribution of health once patents expire, but believe that in order for India to become the ‘innovation nation of the 21st century,’ it should reward and encourage innovation, including incremental innovation, by respecting the significant resources and costs associated with finding new and better cures to treat diseases.”

The U.S.-India Business Council was formed in 1975 at the request of the United States and Indian governments to advance two-way trade and deepen commercial ties. Today, USIBC is the premier business advocacy association comprised of nearly 400 of America’s and India’s top companies dedicated to enhancing the U.S.-India commercial relationship. Ajay Banga, President and CEO of MasterCard, serves as chairman of USIBC.

www.usibc.com

CONTACT

U.S.-India Business Council
Kathryn Van Dyken, 202-463-5768
kvandyken@uschamber.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品が米国臨床腫瘍学会(ASCO)と欧州血液学会(EHA)の年次総会でオンコロジーの広範なポートフォリオとパイプラインのデータを発表
  • ResMed赞助的研究显示,采用居家吸氧与居家无创通气相结合治疗COPD具有成本效益
  • 武田在美国临床肿瘤学会(ASCO)和欧洲血液学会(EHA)年会上重点介绍其强大的肿瘤产品阵容和后续产品线数据
  • AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model
  • GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing